In our study, the proportions of patients with PD‐L1 < 1%, 1–49%, and ≥50% were 76.7%, 14.8%, and 8.5%, respectively, similar to a report from a Chinese population study, where patients with PD‐L1 < 1% accounted for 79% and patients with PD‐L1 ≥ 50% accounted for only 7.6% of lung adenocarcinoma patients.40 The gene discussed is CD274; the disease is lung adenocarcinoma.